Shree Pacetronix [SHREEPAC] vs Poly Medicure [POLYMED] Detailed Stock Comparison

Shree Pacetronix

BSE
Loading...

Poly Medicure

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Shree Pacetronix wins in 8 metrics, Poly Medicure wins in 11 metrics, with 0 ties. Poly Medicure appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricShree PacetronixPoly MedicureBetter
P/E Ratio (TTM)70.4556.04Poly Medicure
Price-to-Book Ratio5.337.41Shree Pacetronix
Debt-to-Equity Ratio36.796.52Poly Medicure
PEG Ratio0.882.92Shree Pacetronix
EV/EBITDA28.7041.67Shree Pacetronix
Profit Margin (TTM)6.03%21.18%Poly Medicure
Operating Margin (TTM)18.43%20.56%Poly Medicure
EBITDA Margin (TTM)18.43%20.56%Poly Medicure
Return on Equity5.44%12.24%Poly Medicure
Return on Assets (TTM)3.25%10.60%Poly Medicure
Free Cash Flow (TTM)$-7.25M$-906.06MShree Pacetronix
Dividend YieldN/A0.33%N/A
1-Year Return31.76%-14.73%Shree Pacetronix
Price-to-Sales Ratio (TTM)4.2411.95Shree Pacetronix
Enterprise Value$770.67M$190.64BPoly Medicure
EV/Revenue Ratio4.4611.29Shree Pacetronix
Gross Profit Margin (TTM)68.11%68.45%Poly Medicure
Revenue per Share (TTM)$48$168Poly Medicure
Earnings per Share (Diluted)$2.89$35.51Poly Medicure
Beta (Stock Volatility)-1.610.04Shree Pacetronix
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Shree Pacetronix vs Poly Medicure Stock Performance Analysis

Loading Price Chart...

Shree Pacetronix
Poly Medicure
Shree Pacetronix Stock Overview | Poly Medicure Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Shree Pacetronix1.98%10.34%41.45%160.52%214.57%67.17%
Poly Medicure3.45%2.52%5.11%-7.50%-9.76%-25.50%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Shree Pacetronix31.76%258.98%1,580.95%869.34%473.21%961.65%
Poly Medicure-14.73%123.03%339.59%965.54%6,026.42%6,026.42%

News Based Sentiment: Shree Pacetronix vs Poly Medicure

Shree Pacetronix

News based Sentiment: MIXED

Shree Pacetronix is experiencing strong positive price momentum, with a 10-day winning streak and a significant cumulative gain since August 4th. However, underlying financial health concerns regarding cash flow and capital allocation, highlighted in earlier September analysis, create a mixed investment picture. The upcoming October 17th earnings report will be crucial in determining whether the company can address these concerns and sustain its recent gains.

View Shree Pacetronix News Sentiment Analysis

Poly Medicure

News based Sentiment: POSITIVE

The acquisition of PendraCare is a significant strategic move for Poly Medicure, expanding its global reach and product portfolio in the cardiology sector. While there are some short-term revenue challenges, the long-term outlook appears positive, supported by analyst ratings and favorable regulatory changes.

View Poly Medicure News Sentiment Analysis

Performance & Financial Health Analysis: Shree Pacetronix vs Poly Medicure

MetricSHREEPACPOLYMED
Market Information
Market Cap i₹747.42M₹201.64B
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i12,847166,882
90 Day Avg. Volume i17,079191,063
Last Close₹216.00₹2,065.40
52 Week Range₹61.11 - ₹216.00₹1,821.20 - ₹3,357.80
% from 52W High0.00%-38.49%
All-Time High₹391.90 (Nov 06, 2023)₹3,357.80 (Oct 28, 2024)
% from All-Time High-44.88%-38.49%
Growth Metrics
Quarterly Revenue Growth0.10%0.05%
Quarterly Earnings Growth0.78%0.26%
Financial Health
Profit Margin (TTM) i0.06%0.21%
Operating Margin (TTM) i0.18%0.21%
Return on Equity (TTM) i0.05%0.12%
Debt to Equity (MRQ) i36.796.52
Cash & Liquidity
Book Value per Share (MRQ)₹38.18₹268.63
Cash per Share (MRQ)₹3.22₹119.26
Operating Cash Flow (TTM) i₹-2,503,000₹2.95B
Levered Free Cash Flow (TTM) i₹7.50M₹3.39B
Dividends
Last 12-Month Dividend Yield iN/A0.33%
Last 12-Month Dividend i₹0.00₹6.50

Valuation & Enterprise Metrics Analysis: Shree Pacetronix vs Poly Medicure

MetricSHREEPACPOLYMED
Price Ratios
P/E Ratio (TTM) i70.4556.04
Forward P/E iN/A259.11
PEG Ratio i0.882.92
Price to Sales (TTM) i4.2411.95
Price to Book (MRQ) i5.337.41
Market Capitalization
Market Capitalization i₹747.42M₹201.64B
Enterprise Value i₹770.67M₹190.64B
Enterprise Value Metrics
Enterprise to Revenue i4.4611.29
Enterprise to EBITDA i28.7041.67
Risk & Other Metrics
Beta i-1.610.04
Book Value per Share (MRQ) i₹38.18₹268.63

Financial Statements Comparison: Shree Pacetronix vs Poly Medicure

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)SHREEPACPOLYMED
Revenue/Sales i₹53.43M₹4.03B
Cost of Goods Sold i₹17.04M₹1.27B
Gross Profit i₹36.39M₹2.76B
Research & Development iN/A₹66.81M
Operating Income (EBIT) i₹9.85M₹828.81M
EBITDA i₹11.81M₹1.49B
Pre-Tax Income i₹8.90M₹1.23B
Income Tax i₹2.26M₹298.63M
Net Income (Profit) i₹6.65M₹930.83M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)SHREEPACPOLYMED
Cash & Equivalents i₹2.54M₹86.99M
Total Current Assets i₹171.89M₹19.17B
Total Current Liabilities i₹88.66M₹3.70B
Long-Term Debt i₹3.61M₹7.71M
Total Shareholders Equity i₹137.82M₹27.66B
Retained Earnings iN/AN/A
Property, Plant & Equipment i₹37.88M₹10.41B

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)SHREEPACPOLYMED
Operating Cash Flow iN/AN/A
Capital Expenditures iN/AN/A
Free Cash Flow iN/AN/A
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricSHREEPACPOLYMED
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Average Daily Volume (10 Day) i12,847166,882
Average Daily Volume (90 Day) i17,079191,063
Shares Outstanding i3.60M101.33M
Float Shares i1.26M33.21M
% Held by Insiders i0.59%0.67%
% Held by Institutions i0.00%0.19%

Dividend Analysis & Yield Comparison: Shree Pacetronix vs Poly Medicure

MetricSHREEPACPOLYMED
Last 12-Month Dividend i₹0.00₹6.50
Last 12-Month Dividend Yield iN/A0.33%
3-Year Avg Annual Dividend i₹0.00₹3.17
3-Year Avg Dividend Yield iN/A0.18%
3-Year Total Dividends i₹0.00₹9.50
Ex-Dividend DateN/ASep 18, 2025